Cargando…

Targeting the EMT transcription factor Snail overcomes resistance to osimertinib in EGFR‐mutant non‐small cell lung cancer

BACKGROUND: The resistance mechanism of the third generation of epidermal growth factor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib is complex. Epithelial mesenchymal transition (EMT) is a common mechanism of EGFR‐TKI acquired resistance. Snail is an important transcription factor related to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qin, Qiong, Li, Xiaoqing, Liang, Xingmei, Zeng, Lili, Wang, Jing, Sun, Linlin, Zhong, Diansheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169301/ https://www.ncbi.nlm.nih.gov/pubmed/33943009 http://dx.doi.org/10.1111/1759-7714.13906

Ejemplares similares

CDK4/6 inhibitor palbociclib overcomes acquired resistance to third‐generation EGFR inhibitor osimertinib in non‐small cell lung cancer (NSCLC)
por: Qin, Qiong, et al.
Publicado: (2020)

Correction to targeting the EMT transcription factor snail overcomes resistance to osimertinib in EGFR‐mutant non‐small cell lung cancer
Publicado: (2023)

Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
por: Tang, Kejing, et al.
Publicado: (2018)

Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer
por: Yochum, Zachary A., et al.
Publicado: (2018)

Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer
por: Raoof, Sana, et al.
Publicado: (2019)

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
por: Zang, Hongjing, et al.
Publicado: (2020)

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
por: Uchibori, Ken, et al.
Publicado: (2017)

ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
por: Ortega-Franco, Ana, et al.
Publicado: (2022)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
por: Lee, Jiyun, et al.
Publicado: (2022)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases
por: Ye, Qiuyue, et al.
Publicado: (2023)

Glycogen synthase kinase‐3 inhibition overcomes epithelial‐mesenchymal transition‐associated resistance to osimertinib in EGFR‐mutant lung cancer
por: Fukuda, Koji, et al.
Publicado: (2020)

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
por: Gen, Soei, et al.
Publicado: (2022)

MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer
por: Yan, Dan, et al.
Publicado: (2022)

Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?
por: Bertoli, Elisa, et al.
Publicado: (2022)

Successful Treatment of EGFR-Mutant Synchronous SCLC and Lung Adenocarcinoma With Osimertinib
por: Batra, Ullas, et al.
Publicado: (2020)

Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2019)

Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer
por: Yi, Yali, et al.
Publicado: (2022)

Trametinib overcomes KRAS‐G12V–induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR‐mutant lung cancer
por: Fukuda, Koji, et al.
Publicado: (2021)

Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report
por: Wilgucki, Molly, et al.
Publicado: (2022)

ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non‐small cell lung cancer
por: Hou, Helei, et al.
Publicado: (2021)

Acquired BRAF gene fusions in Osimertinib resistant EGFR-mutant non-small cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

EGFR exon 19‐deletion aberrantly regulate ERCC1 expression that may partly impaired DNA damage repair ability in non‐small cell lung cancer
por: Zhang, Linlin, et al.
Publicado: (2019)

EGFR‐mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib
por: Hara, Reina, et al.
Publicado: (2021)

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
por: La Monica, Silvia, et al.
Publicado: (2017)

Overcoming EGFR(G724S)-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
por: Fassunke, Jana, et al.
Publicado: (2018)

Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer
por: Lemmon, Christopher A, et al.
Publicado: (2022)

An exploration of the clinical progression models of osimertinib in the treatment of advanced EGFR-mutant non-small cell lung cancer
por: Shi, Yue, et al.
Publicado: (2022)

High kinesin family member 18A expression correlates with poor prognosis in primary lung adenocarcinoma
por: Li, Xiaoqing, et al.
Publicado: (2019)

Retrospective study of EGFR‐mutant lung adenocarcinoma with bone metastatic clinical features
por: Gu, Liyan, et al.
Publicado: (2022)

Overcoming Resistance to Osimertinib by T790M Loss and C797S Acquisition Using Gefitinib in a Patient With EGFR-Mutant NSCLC: A Case Report
por: Enrico, Diego, et al.
Publicado: (2022)

Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer
por: Roper, Nitin, et al.
Publicado: (2020)

Dysregulated expression of microRNA involved in resistance to osimertinib in EGFR mutant non-small cell lung cancer cells
por: Zhang, Dianbao, et al.
Publicado: (2023)

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance
por: Wang, Jiao‐Li, et al.
Publicado: (2022)

PIM1 inhibitor synergizes the anti-tumor effect of osimertinib via STAT3 dephosphorylation in EGFR-mutant non-small cell lung cancer
por: Sun, Ziyi, et al.
Publicado: (2020)

Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer
por: Nanjo, Shigeki, et al.
Publicado: (2018)

Plasma-derived immune-related factors as biomarkers of osimertinib resistance in EGFR-mutant non-small cell lung cancer patients
por: Hydbring, Per
Publicado: (2023)

Case report: Osimertinib administration during pregnancy in a woman with advanced EGFR-mutant non-small cell lung cancer
por: Soberanis Pina, Pamela, et al.
Publicado: (2023)

Osimertinib early dose reduction as a risk to brain metastasis control in EGFR‐mutant non‐small cell lung cancer
por: Tozuka, Takehiro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_076bh42qm0kkvhe89cv5biuq54